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Background: EBV-encoded latent membrane protein 1 (EBV-LMP1) is an important oncogenic protein for
nasopharyngeal carcinoma (NPC) and has been shown to engage a plethora of signaling pathways. Correspondingly,
an LMP1-targeted DNAzyme was found to inhibit the growth of NPC cells both in vivo and in vitro by suppressing cell
proliferation and inducing apoptosis. However, it remains unknown whether an LMP1-targeted DNAzyme would
affect the vasculature of NPC. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been applied
in the clinical trials of anti-angiogenic drugs for more than ten years, and Ktrans has been recommended as a primary
endpoint. Therefore, the objective of the current study was to use DCE-MRI to longitudinally study the effect of an
EBV-LMP1-targeted DNAzyme on the vasculature of patients with NPC.
Methods: Twenty-four patients were randomly divided into two groups: a combined treatment group (radiotherapy +
LMP1-targeted DNAzyme) and a radiotherapy alone group (radiotherapy + normal saline). DCE-MRI scans were
conducted 1 ~ 2 days before radiotherapy (Pre-RT), during radiotherapy (RT 50 Gy), upon completion of radiotherapy
(RT 70 Gy), and three months after radiotherapy (3 months post-RT). Parameters of vascular permeability and
intra- and extravascular volumes were subsequently obtained (e.g., Ktrans, kep, ve) using nordicICE software.
Results: Both Ktrans and kep values for NPC tumor tissues decreased for both groups after treatment. Moreover, a
statistically significant difference in Ktrans values at the pre-therapy and post-therapy timepoints emerged earlier for
the combined treatment group (RT 50 Gy, P =0.045) compared to the radiotherapy alone group (3 months post-RT,
P = 0.032). For the kep values, the downward trend observed for both the combined treatment group and the
radiotherapy alone group were similar. In contrast, ve values for all of the tumor tissues increased following therapy.
Conclusions: The EBV-LMP1-targeted DNAzyme that was tested was found to accelerate the decline of Ktrans values
for patients with NPC. Correspondingly, the LMP1-targeted DNAzyme treatments were found to affect the
angiogenesis and microvascular permeability of NPC.
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Nasopharyngeal carcinoma (NPC) is a common malig-
nancy in southern China. Currently, radiation therapy is
the preferred treatment for this disease. With the emer-
gence of intensity-modulated radiation therapy (IMRT),
local control rates for tumors have significantly increased
[1]. However, increased radiosensitivity, reduced radi-
ation doses, and improved quality of life for NPC patients
remain active areas of research. In particular, receptor-
targeted molecular therapy, as well as the identification
of key genes, regulatory elements, and kinases in NPC
cells, are being studied.
Epstein-Barr virus (EBV) has been implicated in the
pathogenesis of NPC, and EBV-encoded latent membrane
protein 1 (EBV-LMP1)) has been detected in 90% of NPC
clinical samples [2]. EBV-LMP1 is an important onco-
genic protein that has been shown to engage a plethora of
signaling pathways that involve nuclear factor kappa B
(NFκB), c-Jun N-terminal kinase (JNK), c-Jun activator
protein 1 (AP1), mitogen A activated protein kinase (p38a
MAPK), activating transcriptional factor (ATF), Janus kin-
ase (JAK) signal transducers, and activators of transcrip-
tion protein (STAT). Moreover, constitutive activation of
these pathways appears to be central to the ability of
LMP1 to induce multiple morphological and phenotypic
alterations [3]. For example, EBV-LMP1 is involved in the
transformation, proliferation, apoptosis, and differenti-
ation of NPC cells, and has also exhibited a positive effect
on tumor angiogenesis by directly up-regulating expres-
sion of vascular endothelial growth factor (VEGF) via the
Stat 3 transcription factor [4]. Therefore, it has been hy-
pothesized that blocking of EBV-LMP1 represents a novel
targeted molecular therapy for NPC [5].
Deoxyribozymes (DNAzymes) are single-stranded DNA
fragments that have been selected to have catalytic func-
tions and ribozyme activity using in vitro molecular evolu-
tion techniques. DNAzymes have the ability to cleave
RNA with high efficiency [6], and therefore, are able to
inhibit gene expression at the mRNA level and regulate
expression of target proteins [7,8]. Correspondingly,
DNAzymes are potentially applicable to gene inactiva-
tion strategies [9,10]. Previously, a 33-mer oligonucleotide
LMP1-targeted DNAzyme containing three phosphoro-
thioate linkages at its 5’ and 3’ ends was developed to
specifically target LMP1 mRNA [11]. Down-regulation of
LMP1 expression using this LMP1-targeted DNAzyme
was found to inhibit the growth of NPC cells both in vivo
and in vitro by suppressing cell proliferation and inducing
apoptosis [2,12]. Moreover, in a recent study, LMP1-
targeted DNAzyme was found to enhance the radiosensi-
tivity of LMP1-positive NPC cells by inhibiting telomerase
activity [13].
Conventionally, prospective, random, and well-controlled
double-blind trials have been the “gold standard” forevaluating drug safety and effectiveness. Unfortunately,
however, this method has also resulted in the soaring
costs associated with medical innovations. Conse-
quently, it has been proposed that biomarkers could be
used to provide initial evidence regarding drug efficacy
and safety. In recent years, with advances in imaging
technology, imaging biomarkers have been increasingly
utilized to assess drug efficacy. Furthermore, newer im-
aging technologies have been able to provide functional
information in addition to structural information for
several diseases [14].
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) uses fast T1-weighted sequences to assess
changes in signal intensity before, during, and after the
intravenous administration of contrast agent (CA). The dy-
namic contrast images obtained are then used to quantitate
parameters which characterize tumor microcirculation. For
example, the volume constant for the transfer of CA from
the plasma to the extravascular extracellular space (e.g.,
Ktrans minute-1) represents an important parameter, and is
primarily related to blood perfusion and microvessel per-
meability [15]. Over the past 10 years, DCE-MRI and ex-
tracted kinetic parameters have been applied to phase I
and phase II clinical trials of anti-angiogenic drugs and vas-
cular disrupting agents, with Ktrans generally recognized as
a marker of tumor blood flow and permeability [15-17]. In
addition, Ktrans has been recommended as a primary end-
point for anti-cancer treatment trials by the U.S. National
Cancer Institute [18].
Although EBV LMP1 has been shown to promote
tumor angiogenesis [4], it remains unknown whether an
LMP1-targeted DNAzyme affects NPC vasculature. In
the present study, an LMP1-targeted DNAzyme was
injected locally into NPC tissues in conjunction with rad-
ical radiation therapy and DCE-MRI was used to evaluate
the efficacy of this treatment for NPC patients. To the
best of our knowledge, this study is the first to examine
the effects of an LMP1-targeted DNAzyme using DCE-
MRI in vivo.
Methods
Preparation of EBV LMP1-targeted DNAzyme
The EBV LMP1-targeted DNAzyme tested was produced
by Oligos Etc, Inc. (Wilsonville, OR, USA) under Good
Manufacturing Practice conditions. The efficacy, toxicity,
and plasma pharmacokinetics of this LMP1-targeted
DNAzyme was previously evaluated in mice prior to clin-
ical study [2]. Based on the results of these studies, this
LMP1-targeted DNAzyme was found to be safe and well-
tolerated.
Patients and grouping
A total of 24 patients with histologically confirmed
NPC were enrolled in this study and received treatment
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and 6 females who ranged in age from 31–64 years
(Table 1). Poorly differentiated squamous cell carcin-
oma was confirmed by biopsy in all 24 cases, while
EBV-LMP1 positive expression was confirmed with
immunohistochemical techniques. In addition, 17 cases
involved cervical lymph node metastasis, while distant
metastases were not detected in any of the cases.
Protocol design
Twenty-four patients were randomly and double-blindly
divided into two groups: a combined treatment group
(n = 14) or a radiotherapy alone group (n =10) (Table 1).
The randomization of patients was not ideal since six
patients (1 in the combined treatment group and 5 in
the radiotherapy alone group) rejected DCE-MRI. For
both treatment groups, a Varian 2100C/D linear acceler-
ator was used for radiotherapy.
The combined treatment group received radiotherapy
plus an injection of the LMP1-targeted DNAzyme in sa-
line (6 mg/0.1 ml) into each tumor. Regarding the latter,
patients received local anesthesia and an epical endo-
scope was used to guide the injections. The injectionsTable 1 Patient characteristics
Patient no. Gender Age (y) Tumor stage Treatment group
1 F 36 II Combined treatment
2 M 44 II Radiotherapy alone
3 M 63 II Combined treatment
4 F 32 III Combined treatment
5 M 56 III Combined treatment
6 F 45 IVa Radiotherapy alone
7 M 40 III Radiotherapy alone
8 F 44 IVa Combined treatment
9 M 48 II Combined treatment
10 M 60 III Combined treatment
11 M 64 III Radiotherapy alone
12 M 55 III Combined treatment
13 M 43 IVa Radiotherapy alone
14 M 59 II Combined treatment
15 F 56 II Radiotherapy alone
16 M 37 II Combined treatment
17 F 37 II Combined treatment
18 M 41 II Radiotherapy alone
19 M 52 II Combined treatment
20 M 41 II Radiotherapy alone
21 M 31 II Combined treatment
22 M 51 II Combined treatment
23 M 52 II Radiotherapy alone
24 M 62 II Radiotherapy alonewere performed twice a week for five weeks, resulting in
a total volume of 1 ml LMP1-targeted DNAzyme admin-
istered to each tumor. For radiotherapy, a 2 Gy dose was
administered five times a week for seven weeks, resulting
in a total dose of 70 Gy.
For the radiotherapy alone group, the program and
dose of radiotherapy were the same as that described for
the combined treatment group. In addition, the patients
received local anesthesia for injections of saline (0.1 ml
each) that were administered using an epical endoscope.
Injections were performed twice a week for five weeks,
resulting in a total volume of 1 ml saline administered to
each tumor.
This study was conducted in accordance with the
International Conference on Harmonization-Good Clin-
ical Practice. Approval for this study was obtained from
the Human Ethics Committee of the Xiangya Hospital,
Central South University, and written consent was ob-
tained from each participant. Approval was also obtained
from the Ministry of Science and Technology.
MRI protocol
All patients underwent conventional MRI and DCE-MRI
scans 1 ~ 2 days prior to the start of radiotherapy (Pre-
RT). Subsequent scans were performed during the radio-
therapy treatment period after a radiation dose of 50 Gy
had been achieved (RT 50 Gy), at the end of radiotherapy
when a total radiation dose of 70 Gy had been applied (RT
70 Gy), and three months after radiotherapy (3 months
post-RT). MRI was performed using a 1.5 T system
(MAGNETOM Sonata, Siemens, Erlangen, Germany).
Conventional MRI
Unenhanced axial T1-weighted (repetition time/echo time
[TR/TE] 450/10 ms, field of view [FOV] 230 × 230 mm,
section thickness 5 mm, intersection gap 1.5 mm, 19 sec-
tions) and axial T2-weighted (TR/TE 4200/98 ms) images
were obtained. Contrast-enhanced and fat-suppression T1-
weighted images (TR/TE 450/10) were obtained following
the DCE-MRI scans.
DCE-MRI
DCE-MRI was acquired using a TurboFLASH sequence
before, during, and after an intravenous injection of CA
was made. Ten axial sections were selected from through-
out the tumor on the basis of T2-weighted imaging. Pa-
rameters were as follows: TR/TE 199 ms/1.05 ms, inverse
time 100 ms, FOV 260 mm× 210 mm, matrix 128 × 96,
flip angle 20°, section thickness 6 mm, intersection gap
1.2 mm, time resolution 4 s. A series of 90 multisection
sets were acquired in 360 s. At the end of the sixth acqui-
sition, a standard dose (0.2 mmol/kg body weight) bolus
of CA (Magnevist, Bayer Schering Pharma AG, Berlin,
Germany) was injected via the antecubital vein at a rate of
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linckrodt), followed by a 20 ml bolus of saline at a rate of
4 ml/s.
Image postprocessing
The original DCE-MRI data were transferred to an inde-
pendent workstation and processed using a nordicICE soft-
ware package (Nordic Image Control and Evaluation
Version 2.3.6; Nordic Imaging Lab, Bergen, Norway). First,
the arterial input function (AIF) was automatically obtained
from a region of interest (ROI) drawn on the internal ca-
rotid artery located in close proximity to the tumor. Sec-
ondly, based on Tofts-kermode two compartment kinetic
modeling theory [19], deconvolution of the tissue response
curves (dynamic curves for all pixels) was performed using
the AIF according to Keunen [20]. Qualitative, as well as
quantitative, maps of several parameters (including Ktrans,
kep, ve) related to vascular permeability and intra- and extra-
vascular volumes were subsequently obtained. To calculate
the Ktrans for each tumor, a ROI (with a diameter of 9-
10 pixels, or 60-70 mm2) was placed on the tumor paren-
chyma where the Ktrans value was the highest. For the same
ROI, the other parameters were calculated. Ktrans represents
the rate constant for the transfer of CA from plasma to the
extravascular extracellular space (EES). In addition, kep is
the rate constant for the transfer of CA from EES to
plasma, and ve is the CA distribution volume. These pa-
rameters are related as follows: ve = (K
trans/kep).
Safety evaluation
Adverse events were reviewed at each patient visit. Blood
samples were also collected from patients prior to radio-
therapy, during radiotherapy (after 50 Gy), and three
months after radiotherapy. Analyses of blood chemistry,
as well as liver and renal function, were evaluated. Im-
pairment of the skin, mucous membranes, and salivary
gland are common characteristics of radiation therapy,
and their incidence was analyzed using the Wilcoxon
rank sum test.
Statistical analysis
All data are expressed as the mean ± standard deviation
(SD), and confidence intervals are included in the figures.
Using Student’s t-test, values between the different
groups were compared. In addition, the values at various
timepoints were compared for the same group using the
Student-Newman-Keuls (SNK)-q test. A P-value less than
0.05 was considered statistically significant. Statistical
analyses were performed using SPSS (version 17.0; SPSS
Inc., Chicago, IL, USA).
Results
To validate whether DCE-MRI can monitor the thera-
peutic efficacy of this treatment approach for NPCpatients, parameters of vascular permeability and intra-
and extravascular volumes were subsequently obtained
(including Ktrans, kep, ve). Prior to radiotherapy, there
were no statistically significant differences in the Ktrans
for the tumor tissues of the combined treatment group
versus the tumor tissues of the radiotherapy alone group
(t-test, P =0.175). However, for both groups, the 95%
confidence interval (CI) of the Ktrans values declined
gradually from the Pre-RT timepoint to the 3 months
post-RT timepoint (Figure 1A). Moreover, for the com-
bined treatment group, statistically significant differences
in the Ktrans values were observed between the Pre-RT
timepoint and the RT (50 Gy), RT (70 Gy), and 3 months
post-RT timepoints. In particular, the latter values were
lower than the Ktrans value for the Pre-RT timepoint. In
contrast, the radiotherapy alone group exhibited no
significant differences in the Ktrans values between the
Pre-RT and the RT (50 Gy) and RT (70 Gy) timepoints.
However, there was a statistically significant difference
between the Ktrans values for the Pre-RT and 3 months
post-RT timepoints for the radiotherapy alone group
(Table 2). Representative Ktrans maps are shown in
Figures 2 and 3.
There were no statistically significant differences in the
kep values for tumor tissues between the combined treat-
ment group and the radiotherapy alone group before
radiotherapy (t-test, P =0.770). However, for both groups,
the kep values gradually declined following therapy. The
95% CI for the kep values are shown in Figure 1B. When
kep values were compared for the four timepoints, statis-
tically significant differences were observed between the
Pre-RT timepoint and the RT (50 Gy), RT (70 Gy), and
3 months post-RT timepoints for the combined treat-
ment group, and the radiotherapy alone group. In par-
ticular, the latter values were lower than the kep value for
the Pre-RT timepoint (Table 3). Representative kep maps
are shown in Figures 2 and 3.
Statistically significant differences were observed between
the ve values for the Pre-RT timepoint and the RT (50 Gy),
RT (70 Gy), and 3 months post-RT timepoints for all tumor
tissues. Furthermore, the latter values were higher than the
ve value for the Pre-RT timepoint (Table 4).
Conventional MRI was performed for all of the partici-
pants and was accompanied by DCE-MRI. Enhancement
of the tumor parenchyma was observed in both contrast-
enhanced and fat-suppression T1-weighted images. The
majority of the tumor lesions exhibited a reduction in
tumor volume rapidly after treatment. Moreover, two le-
sions in the combined treatment group and one lesion in
the radiotherapy alone group disappeared completely
three months after the patients received radiotherapy.
Tumor volumes were measured from contrast-enhanced
and fat-suppression T1-weighted images by two special-
ists (an oncologist and a radiologist) using the Varian
Figure 1 Ktrans values (A) and kep values (B) their associated 95% CIs are shown for the Pre-RT, RT (50 Gy), RT (70 Gy), and 3 months
post-RT timepoints for the combined treatment group and the radiotherapy alone group. The Ktrans values for the NPC tumor tissues
decreased in both groups. Furthermore, statistically significant differences in the pre-therapy and post-therapy Ktrans values emerged earlier in the
combined treatment group (RT 50 Gy) compared to the radiotherapy alone group (3 months post-RT) (A). In both groups, the kep values declined
gradually following therapy (B).
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ment group, the mean tumor shrink rate 3 months post-
RT was significantly higher than that for the radiotherapy
alone group (97.78 ± 5.81% and 87.78 ± 15.20%, respect-
ively; P = 0.038).
There were no adverse events that could be attributed
to LMP1-targeted DNAzyme injections. Furthermore,
analyses of white blood cell number, hemoglobin concen-
tration, platelet number, and lymphocyte cell number
showed no significant differences between the combined
treatment group and the radiotherapy alone group. There
were also no significant differences in liver or renal func-
tion, or in impairment of skin, mucous membranes, or
salivary gland, between the two treatment groups.
Discussion
Studies have shown that DCE-MRI can be used to monitor
the efficacy of various treatments and to predict response
to treatment. In particular, this has been demonstrated for
neoadjuvant chemotherapy and radiation therapy for blad-
der cancer, breast cancer, and osteosarcomas [21,22]. Over
the past 10 years, studies have also shown that DCE-MRITable 2 Comparison of Ktrans values for different timepoints f
Timepoints Combined treatment group
n Mean ± SD P
Pre-RT 14 0.2048 ± 0.0606
RT (50 Gy) 12 0.1573 ± 0.0605 0
RT (70 Gy) 14 0.1382 ± 0.0671 0
3 months post-RT 12 0.0862 ± 0.0413 0
Comparison of Ktrans values for the Pre-RT, RT (50 Gy), RT (70 Gy), and three months
alone group.
*Comparison between Pre-RT and RT (50 Gy); **Comparison between Pre-RT and RTand extracted kinetic parameters can be used as an in vivo
cancer imaging tool for the diagnosis, monitoring of treat-
ment effect, and evaluation of anti-cancer drugs. Corres-
pondingly, this method has been applied to phase I and
phase II clinical trials of anti-angiogenic drugs and vascular
disrupting agents [23,24]. In particular, Ktrans is currently
recognized as a general marker of tumor blood flow
[15-17], and has been recommended as a primary endpoint
for an anti-cancer treatment trial conducted by the U.S.
National Cancer Institute [18]. DCE-MRI has been widely
used in the development of anti-angiogenic drugs, and has
detected the efficacy of drugs earlier than conventionally
observed changes in tumor volume. This is particularly
beneficial for the selection of individualized patient treat-
ment plans for patients that are diagnosed in the early
stages of disease [25]. In a summary by O'Connor et al.
describing their experience with DCE-MRI for the early
clinical development of vascular-directed anticancer ther-
apies over the past decade, they demonstrated that perfu-
sion imaging provides unique information regarding the
vascular properties of tumors, and for tumor responses to
antiangiogenic agents and VDAs in pre-clinical and earlyor the two groups
Radiotherapy alone group
-value n Mean ± SD P-value
10 0.1693 ± 0.0619
.045* 10 0.1652 ± 0.0518 0.8231*
.004** 9 0.1414 ± 0.0363 0.4262**
.000*** 9 0.1096 ± 0.0424 0.0323***
post-RT timepoints for the combined treatment group and the radiotherapy
(70 Gy); ***Comparison between Pre-RT and 3 months post-RT.
Figure 2 The change of Ktrans values (A) and kep values (B) and their associated 95% CIs for different timepoints for the combined
treatment group and the radiotherapy alone group. The Ktrans value of the tumor for pre-RT, RT 50 Gy, RT 70 Gy and 3 months post-RT time-
point is 0.2391, 0.1684, 0.1623, 0.1012 (minute-1) respectively, which demonstrates a significant decrease in the Ktrans at the RT 50 Gy timepoint,
and the kep value is 1.2913, 0.7172, 1.0940, 0.4545 (minute
-1) respectively.
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marker for certain chemotherapy drugs in order to separ-
ate the biological effects of chemotherapy from those
related to angiogenesis inhibitors [26].
To investigate the effects of an EBV LMP1-targeted
DNAzyme on NPC vasculature in the present study, two
methods were compared (e.g., radiation therapy in com-
bination with a LMP1-targeted DNAzyme and radiation
therapy alone) using DCE-MRI. It was observed that the
Ktrans values for NPC tumor tissues decreased for both
treatment groups over the course of treatment. Ktrans is
a factor that accounts for the complex functions of
blood flow, endothelial surface area, and endothelial per-
meability. However, it can also have multiple physiologic
interpretations depending on the balance between capil-
lary permeability and blood flow in a tissue. In high-
permeability situations (where flux across the endothe-
lium is flow limited), Ktrans is equal to the blood plasma
flow per unit volume of tissue. Conversely, for low
permeability conditions where tracer flux is perme-
ability limited, the Ktrans value is equal to the perme-
ability surface area product per unit volume of tissue
[19]. NPC tumor tissues are characterized by extensiveangiogenesis, an incomplete vascular basement mem-
brane, and high permeability. Thus, NPC tumor tissues
exhibit high permeability conditions, with leakage of CA
to the EES being rapid and of great quantity. Accord-
ingly, the Ktrans value for NPC tissue is very high. In con-
trast, muscle tissue, fibrous tissue, normal brain tissue,
and tumor tissues in the late stages of chemotherapy or
radiation therapy are characterized by low permeability.
The Ktrans value for these tissue types is dependent on
cross-vessel wall transport, and it is significantly lower
than the Ktrans value for tumor tissues [27,28]. Swelling,
degeneration, and necrosis of tumor capillary walls, as
well as narrowing of vessel lumen and thrombosis due to
radiotherapy, also contribute to decreased permeability
and reduced perfusion, thereby resulting in a lower
Ktrans value. Many studies have reported on the prognos-
tic value of Ktrans and other DCE-MRI parameters in
assessing the response to radiotherapy, which, however,
demonstrated contrary findings. Longitudinal study and
repeated DCE-MRI may reduce these discrepancies, and
be recommended [29].
A decrease in the Ktrans values for the NPC tumor tis-
sues was observed significantly earlier (e.g., at the RT
Figure 3 Patient 20 of the radiotherapy alone group (radiotherapy + normal saline). The Ktrans value of the tumor for pre-RT, RT 50 Gy, RT
70 Gy and 3 months post-RT timepoint is 0.1891, 0.1622, 0.1429, 0.0633 (minute-1) respectively, which shows a significant decrease in the Ktrans at
3 months post-RT, and the kep value is 0.5338, 0.3982, 0.3570, 0.0900 (minute
-1) respectively.
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in the radiotherapy alone group (3 months post-RT).
These results suggest that LMP1-targeted DNAzymes
accelerate the decline of the Ktrans value for NPC. It has
previously been shown that EBV LMP1 promotes tumor
angiogenesis by up-regulating VEGF expression via acti-
vation of Stat 3 transcriptional factor [3]. Although the
relationship between DCE-MRI and VEGF remains un-
clear, a positive correlation between levels of soluble vas-
cular endothelial growth factor recptor-1 (sVEGFR-1)
and sVEGFR-2 in plasma and Ktrans for patients with
advanced ovarian cancer were observed in a previous
study [30]. Taken together, these observations suggestTable 3 Comparison of kep values for different timepoints for
Timepoints Combined treatment group
n Mean ± SD
Pre-RT 14 0.8550 ± 0.2978
RT (50 Gy) 12 0.51672 ± 0.2845
RT (70 Gy) 14 0.5332 ± 0.3347
3 months post-RT 12 0.3216 ± 0.1339
Comparison of kep values for the Pre-RT, RT (50 Gy), RT (70 Gy), and three months p
alone group. *Comparison between Pre-RT and RT (50 Gy); **Comparison between Pthat LMP1-targeted DNAzyme treatment affects the
angiogenesis and microvascular permeability of NPC,
and this can be proved with further pathology and mo-
lecular biology studies of NPC.
In cancer treatment trials, kep and ve values have been
recommended as secondary endpoints [31]. In the
present study, tumor tissues of both the combined treat-
ment group and the radiotherapy alone group had kep
values that declined following therapy due to the slower
transfer of CA from the EES to plasma as a result of de-
creased permeability. This similar trend in kep values for
both groups suggests that the decrease is mainly related
to the radiation treatments. In contrast, ve values for allthe two groups
Radiotherapy alone group
P-value n Mean ± SD P-value
10 0.8163 ± 0.3398
0.004* 10 0.5688 ± 0.2337 0.027*
0.003** 9 0.4644 ± 0.1087 0.003**
0.000*** 9 0.3703 ± 0.2051 0.000***
ost-RT timepoints for the combined treatment group and the radiotherapy
re-RT and RT (70 Gy); ***Comparison between Pre-RT and 3 months post-RT.
Table 4 Comparison of the ve values for the Pre-RT, RT
(50 Gy), RT (70 Gy), and 3 months post-RT timepoints for
all of the NPC tissues examined
Timepoints n ve
Mean ± SD P-value
Pre-RT 24 0.2359 ± 0.0754
RT (50 Gy) 22 0.3316 ± 0.1360 0.009*
RT (70 Gy) 23 0.3195 ± 0.1327 0.020**
3 months post-RT 21 0.3138 ± 0.1316 0.033***
*Comparison between Pre-RT and RT (50 Gy); **Comparison between Pre-RT
and RT (70 Gy); ***Comparison between Pre-RT and 3 months post-RT.
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and this is consistent with an increase in EES secondary
to the loss of tumor cells with radiation exposure. More-
over, continuous accumulation of CA in the EES is con-
sistent with a slower transfer of CA from EES to plasma
post-therapy [31,32].
There were limitations associated with the present
study. First, since surgery is not the preferred treatment
for NPC, a comparison of pathology and DCE-MRI was
not conducted. Secondly, the majority of the tumor le-
sions examined exhibited reduced tumor volume and
disappeared quickly following treatment. Consequently,
there was a lack of DCE-MRI data after the first year fol-
lowing treatment. Lastly, the parameters examined were
based on the use of a tracer-kinetic model, which as-
sumes that transcytolemmal water exchange contributes
negligibly to changes in signal intensity [33]. Therefore,
the amount of CA in tissues could be overestimated.
Conclusions
The use of an EBV LMP1-targeted DNAzyme was found
to accelerate the decline of Ktrans values for NPC tissues,
thereby suggesting that this DNAzyme affects the angio-
genesis and microvascular permeability of NPC in vivo.
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